Press Releases

Date Title
15 Nov. 2022 Illumina To Webcast Upcoming Investor Conferences
8 Nov. 2022 Illumina Boosts Genomics Innovation in the Emirates Through New State-of-the-Art Solutions Center
3 Nov. 2022 Illumina Reports Financial Results for Third Quarter of Fiscal Year 2022
1 Nov. 2022 Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States
18 Oct. 2022 Illumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis
17 Oct. 2022 Illumina to Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022
11 Oct. 2022 Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery
6 Oct. 2022 Illumina to Announce Third Quarter 2022 Financial Results on Thursday, November 3, 2022
29 Sep. 2022 Illumina Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum
29 Sep. 2022 Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health
26 Sep. 2022 Illumina Genomics Forum Sold Out, Announces Opportunity to View Innovation Roadmap Session via Livestream
19 Sep. 2022 Illumina to Host Upcoming Investor Day
19 Sep. 2022 Illumina Genomics Forum to Feature Nobel Laureate Frances Arnold as part of Distinguished Panel on How the Genomics Revolution Is Transforming Patient Care
14 Sep. 2022 Illumina Accelerator Invests in the Fifth Global Funding Cycle of Startups Advancing Breakthrough Therapeutics, Diagnostics, Women's Health, and Sustainable Agriculture Applications
12 Sep. 2022 Illumina Genomics Forum to Convene Leading Visionaries to Explore Architecting Health's Radically New Infrastructure
8 Sep. 2022 Illumina Announces Opportunity to View Live Webcast of Illumina Genomics Forum Innovation Roadmap Session Followed by Investor Conference Call
7 Sep. 2022 Illumina Genomics Forum to Feature Diverse Lineup of Visionary Global Leaders
6 Sep. 2022 Illumina Intends to Appeal European Commission's Decision in GRAIL Deal
5 Sep. 2022 Latest Research at ESMO Congress 2022 Showcases the Impact of Comprehensive Genomic Profiling for Cancer Patients
1 Sep. 2022 Administrative Law Judge Rules in Favor of Illumina in FTC Challenge of GRAIL Deal
30 Aug. 2022 Illumina Deepens Commitment to Customers in China with New Manufacturing Site
29 Aug. 2022 Illumina Genomics Forum to Feature Tennis Legend Chris Evert on the Role Genomics Played in her Cancer Fight
22 Aug. 2022 Illumina Genomics Forum to Feature 23andMe Co-founder and CEO Anne Wojcicki
16 Aug. 2022 Minderoo Foundation and Illumina Commit $40M AUD to Apply Advanced Genomics to Marine Conservation
15 Aug. 2022 Illumina Genomics Forum to Feature American Cancer Society CEO Karen Knudsen on the Future of Cancer Genomics
11 Aug. 2022 Illumina Reports Financial Results for Second Quarter of Fiscal Year 2022
8 Aug. 2022 Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics
27 Jul. 2022 Illumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities
18 Jul. 2022 Illumina Announces Inaugural Illumina Genomics Forum with a Conversation with Former U.S. President Barack Obama
14 Jul. 2022 Illumina to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
14 Jul. 2022 Illumina Among First in the World to Receive Approval of Science-Based Net-Zero Target
28 Jun. 2022 Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health
22 Jun. 2022 Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome
9 Jun. 2022 Joydeep Goswami Appointed Interim CFO; Sam Samad To Depart Illumina
7 Jun. 2022 Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions
2 Jun. 2022 Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO
24 May 2022 Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy
18 May 2022 Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care
5 May 2022 Illumina Reports Financial Results for First Quarter of Fiscal Year 2022
5 May 2022 Illumina and Deerfield Management partner to accelerate drug development
28 Apr. 2022 Illumina To Webcast Upcoming Investor Conference
25 Apr. 2022 Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children
14 Apr. 2022 Illumina to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
12 Apr. 2022 Illumina Expands Access to Genomics in Latin America through New State-of-the-Art Solution Center
11 Apr. 2022 John Frank Joins Illumina as Chief Public Affairs Officer
7 Apr. 2022 Illumina Releases Annual Corporate Social Responsibility Report
16 Mar. 2022 Illumina Accelerator Invests in Seven Omics Startups Advancing Breakthrough Therapeutics, Diagnostics, DNA Storage, Mental Wellness, and Sustainable Foods Applications
15 Mar. 2022 Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe
14 Mar. 2022 Illumina Welcomes Carissa Rollins as Chief Information Officer
21 Feb. 2022 Illumina To Webcast Upcoming Investor Conference
10 Feb. 2022 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2021
3 Feb. 2022 Illumina To Webcast Upcoming Investor Conferences
3 Feb. 2022 Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer
24 Jan. 2022 Illumina collaborates with National Cancer Center Japan to address a leading cause of death in Asia
20 Jan. 2022 Illumina to Announce Fourth Quarter & Full Year 2021 Financial Results on Thursday, February 10, 2022
10 Jan. 2022 Illumina collaborates with Nashville Biosciences to accelerate medicines development
10 Jan. 2022 Illumina Partners with Agendia to Expand Genomic Testing in Breast Cancer Care
10 Jan. 2022 Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership
10 Jan. 2022 Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference
5 Jan. 2022 Illumina Enters Co-Development Partnership with SomaLogic